Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter observational study to determine real-life efficacy and safety of Upadacitinib in treatment of Psoriatic arthritis

Next Previous
Trial Profile

A multicenter observational study to determine real-life efficacy and safety of Upadacitinib in treatment of Psoriatic arthritis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ankylosing spondylitis; Psoriatic arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms UP-REAL

Most Recent Events

  • 10 Jul 2023 New trial record
  • 03 Jul 2023 According to Results presented at the 24th Annual Congress of the European League Against Rheumatism, Data about assessment until week 56 (T12) for all patients will be presented in a future work.
  • 03 Jun 2023 Results (n=126) reporting preliminary data at week24 presented at the 24th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top